NextCure, Inc. (NXTC)
| Market Cap | 212.32M |
| Revenue (ttm) | 22.38M |
| Net Income (ttm) | -36.60M |
| Shares Out | 27.53M |
| EPS (ttm) | -1.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $7.86 |
| Previous Close | $7.69 |
| Change ($) | 0.17 |
| Change (%) | 2.21% |
| Day's Open | 7.83 |
| Day's Range | 7.63 - 7.99 |
| Day's Volume | 480,483 |
| 52-Week Range | 7.63 - 39.77 |
BELTSVILLE, Md., April 28, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...
BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...
BELTSVILLE, Md., April 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...
BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...
BELTSVILLE, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...
BELTSVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...
Los Angeles, California--(Newsfile Corp. - February 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc....
LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.
BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...
LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (“NextCure” or “th...
BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...
NextCure (NXTC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC). Such investors are advised to contact...
BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...
NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class actio...
New York, New York--(Newsfile Corp. - November 19, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November...
Los Angeles, California--(Newsfile Corp. - November 18, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. ...
LOS ANGELES--(BUSINESS WIRE)---- $NXTC #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action fil...
Los Angeles, California--(Newsfile Corp. - November 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc....
Los Angeles, California--(Newsfile Corp. - November 16, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc....
NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14...
Los Angeles, California--(Newsfile Corp. - November 13, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc....
Los Angeles, California--(Newsfile Corp. - November 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. ...
New York, New York--(Newsfile Corp. - November 7, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November ...
BELTSVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclu...
New York, New York--(Newsfile Corp. - October 31, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5...
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14...
New York, New York--(Newsfile Corp. - October 23, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November ...
LOS ANGELES, Oct. 22, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on b...
New York, New York--(Newsfile Corp. - October 17, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5...
New York, New York--(Newsfile Corp. - October 12, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5...
NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14,...
BENSALEM, Pa., Oct. 8, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behal...
LOS ANGELES, Oct. 6, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Nex...
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclu...
New York, New York--(Newsfile Corp. - October 2, 2020) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of N...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NextCure, Inc. ("NextCure” or "the Company") (NASDAQ:NXTC) and certain...
BENSALEM, Pa.--(BUSINESS WIRE)---- $NXTC #CLASSACTION--DEADLINE REMINDER: Law Offices of Howard G. Smith Reminds Investors of Deadline in the Class Action Against NextCure,Inc.(NXTC)on Behalf of Investors
New York, New York--(Newsfile Corp. - October 1, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) of...
New York, New York--(Newsfile Corp. - September 30, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NextCure, Inc. ("NextCure" or "the Co...
LOS ANGELES--(BUSINESS WIRE)---- $NXTC #CLASSACTION--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action of a Securities Class Action Lawsuit Against NextCure, Inc. (NXTC)
NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of NextCure, Inc. (NA...
NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has be...
LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.
NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that: (i) purchased or acqu...
SAN DIEGO & BELTSVILLE, Mass.--(BUSINESS WIRE)---- $NXTC #ClassAction--Shareholder rights law firm Robbins LLP announces that an investor of NextCure, Inc. (NASDAQ: NXTC) filed a class action against th...
LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.
About NXTC
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1;... [Read more...]
| Industry Biotechnology | IPO Date May 9, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol NXTC |
Financial Performance
In 2020, NextCure's revenue was $22.38 million, an increase of 252.58% compared to the previous year's $6.35 million. Losses were -$36.60 million, 8.50% more than in 2019.
Analyst Forecasts
According to 9 analysts, the average rating for NextCure stock is "Buy." The 12-month stock price forecast is 19.38, which is an increase of 146.56% from the latest price.